VisionX, a China-based ophthalmology medical device developer backed by conglomerate Fosun, has secured over $100m in series B funding, DealStreetAsia reported on Friday.
New investors Temasek and Lake Bleu Capital participated in the round alongside returning backers Sequoia Capital China, 3H Health Investment, Sherpa Healthcare Partners and Highlight Capital.
Founded in 2018, VisionX provides medical equipment to treat eyesight problems such as myopia, ocular surface disease and other corrections and diagnostics.
The company also sells more consumer-focused products like contact lens care equipment. The funding will be used to boost research and development, grow its team and advance its commercialisation efforts.
VisionX had secured over $15m in a pre-series B round earlier this year featuring Fosun subsidiary Fosun Capital, Green Pine Capital Partners, Sequoia Capital China, Sherpa Healthcare Partners, 3H Health, Highlight Capital and Yuanbio Venture Capital, according to DealStreetAsia.
Sequoia Capital had previously led VisionX’s series A round, which closed in August 2020 at more than $14.3m and which included Sherpa Healthcare Partners, BioVenture, Hengqin Financial Investments and unnamed others.
